B7-2/CD86 Antibody (BLR030F)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-76417

Recombinant Monoclonal Antibody.
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP2-76417
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Western Blot

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # BLR030F

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all B7-2/CD86 Antibodies »

Product Specifications

Immunogen

Immunogen sequence between amino acids 300 and 329

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for B7-2/CD86 Antibody (BLR030F)

Immunoprecipitation: B7-2/CD86 Antibody (BLR030F) [NBP2-76417]

Immunoprecipitation: B7-2/CD86 Antibody (BLR030F) [NBP2-76417]

Immunoprecipitation: B7-2/CD86 Antibody (BLR030F) [NBP2-76417] - Detection of human CD86 by WB of immunoprecipitates from HDML-2 lysate. Antibodies: Rabbit anti-CD86 recombinant monoclonal [BLR030F] (NBP2-76417) and rabbit anti-CD86 recombinant monoclonal [BLR029F] (NBP2-76416).
B7-2/CD86 Antibody (BLR030F)

Western Blot: B7-2/CD86 Antibody (BLR030F) [NBP2-76417] -

Western Blot: B7-2/CD86 Antibody (BLR030F) [NBP2-76417] - Whole cell lysate (10 µg) from HEK293T, HDLM-2, Jurkat,MJ, and HeLa cells prepared using NETN lysis buffer.Antibody: Rabbit anti-CD86 recombinant monoclonalantibody [BLR030F] used at 1:1000.Secondary: HRP-conjugated goat anti-rabbit IgG. Detection: Chemiluminescence with anexposure time of 10 seconds.
B7-2/CD86 Antibody (BLR030F)

Flow Cytometry: B7-2/CD86 Antibody (BLR030F) [NBP2-76417] -

Flow Cytometry: B7-2/CD86 Antibody (BLR030F) [NBP2-76417] - Antibody: Rabbit anti-CD86 recombinantmonoclonal [BLR030F] or isotype control(unshaded). Secondary: DyLight® 488-conjugated goatanti-rabbit IgG.
View 2 more images

Applications for B7-2/CD86 Antibody (BLR030F)

Application
Recommended Usage

Flow Cytometry

Fixed and permeabilized cells were stained with 0.2 µl per 1 x 10^6

Immunocytochemistry/ Immunofluorescence

1:100 - 1:500

Immunohistochemistry

1:100 - 1:500

Immunoprecipitation

6 µl/mg lysate

Western Blot

1:1000
Application Notes
Epitope retrieval with citrate buffer pH6.0 is recommended for FFPE tissue sections.

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Formulation

Borate Buffered Saline (BBS) pH 8.2

Preservative

0.09% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 2 - 8 C / 1 year from date of receipt

Background: B7-2/CD86

B7-2, also referred to as CD86, is a glycosylated type 1 membrane protein that is a member of the immunoglobulin (Ig) superfamily (1). B7-2/CD86 is constitutively expressed on antigen presenting cells (APCs) such as dendritic cells (DCs), macrophages, and B cells and functions in controlling immune responses through either costimulatory or coinhibitory signals (1,2). Expression of B7-2 is upregulated by APCs upon activation and can be induced in T cells (1,3). The human B7-2 protein, encoded by the CD86 gene, is 329 amino acids (aa) in length with a theoretical molecular weight (MW) of 37.6 kDa (4). The B7-2 protein contains characteristic Ig variable-like (IgV) and constant-like (IgC) domains within its extracellular region (1,3). B7-2/CD86 has structural similarity and shares ~25% sequence homology with another B7 family molecule, B7-1/CD80 (3,5). Both B7-1 and B7-2 are ligands for the activating receptor CD28 and the regulatory receptor cytotoxic T-lymphocyte antigen 4 (CTLA-4) which are expressed on subsets of T cells (1-3,5-7). However, B7-1 and B7-2 bind to CTLA-4 with higher affinity than CD28 (3,5,6). B7-2/CD86 binding to CD28 results in costimulatory signals to promote T cell activation, proliferation, and cytokine production (1-3. 5-7). Binding to CTLA-4 initiates coinhibitory signaling to attenuate the pro-inflammatory T cell response, while also promoting the suppressive function of regulatory T (Treg) cells through expression of indoleamine 2,3-deoxygenase (IDO) (1-3,6,7). Molecules involved in T cell co-signaling have become considerable targets of interest for cancer immunotherapy (7). The anti-CTLA-4 monoclonal antibody ipilimumab, first approved for the treatment of metastatic melanoma, prevents B7-1/B7-2 molecules from binding to CTLA-4, thus driving B7-CD28 binding and promoting costimulatory signals and antitumor effects (1,7,8). Combination therapies targeting co-signaling molecules are currently under investigation to improve antitumor response for treatment of both melanoma and non-melanoma cancers (7,8).

References

1. Collins M, Ling V, Carreno BM. The B7 family of immune-regulatory ligands. Genome Biol. 2005;6(6):223. https://doi.org/10.1186/gb-2005-6-6-223

2. Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy. Blood. 2013;121(5):734-744. https://doi.org/10.1182/blood-2012-10-385591

3. Bolandi N, Derakhshani A, Hemmat N, et al. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. Int J Mol Sci. 2021;22(19):10719. https://doi.org/10.3390/ijms221910719

4. Uniprot (P42081)

5. Bhatia S, Edidin M, Almo SC, Nathenson SG. B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol Lett. 2006;104(1-2):70-75. https://doi.org/10.1016/j.imlet.2005.11.019

6. Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Sci. 2019;110(7):2080-2089. https://doi.org/10.1111/cas.14069

7. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition [published correction appears in Nat Rev Immunol. 2013 Jul;13(7):542]. Nat Rev Immunol. 2013;13(4):227-242. https://doi.org/1010.1038/nri3405

8. Karimi A, Alilou S, Mirzaei HR. Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab. Front Oncol. 2021;11:624780. https://doi.org/101010.3389/fonc.2021.624780

Alternate Names

B72, CD86

Gene Symbol

CD86

Additional B7-2/CD86 Products

Product Documents for B7-2/CD86 Antibody (BLR030F)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for B7-2/CD86 Antibody (BLR030F)

This Product sold under License from Bethyl Laboratories, Inc.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.